IL136867A0 - Triazine compounds for treatment of cns disorders - Google Patents
Triazine compounds for treatment of cns disordersInfo
- Publication number
- IL136867A0 IL136867A0 IL13686798A IL13686798A IL136867A0 IL 136867 A0 IL136867 A0 IL 136867A0 IL 13686798 A IL13686798 A IL 13686798A IL 13686798 A IL13686798 A IL 13686798A IL 136867 A0 IL136867 A0 IL 136867A0
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- cns disorders
- triazine compounds
- triazine
- cns
- Prior art date
Links
- 150000003918 triazines Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9726987.2A GB9726987D0 (en) | 1997-12-22 | 1997-12-22 | Compounds |
| PCT/EP1998/008273 WO1999032462A1 (en) | 1997-12-22 | 1998-12-18 | Triazine compounds for treatment of cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL136867A0 true IL136867A0 (en) | 2001-06-14 |
Family
ID=10823992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13686798A IL136867A0 (en) | 1997-12-22 | 1998-12-18 | Triazine compounds for treatment of cns disorders |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US6265405B1 (es) |
| EP (1) | EP1042304A1 (es) |
| JP (1) | JP2001526275A (es) |
| KR (1) | KR20010024800A (es) |
| CN (1) | CN1284951A (es) |
| AP (1) | AP2000001846A0 (es) |
| AR (1) | AR014146A1 (es) |
| AU (1) | AU753874B2 (es) |
| BR (1) | BR9814495A (es) |
| CA (1) | CA2315620A1 (es) |
| CO (1) | CO5011066A1 (es) |
| EA (1) | EA200000561A1 (es) |
| EE (1) | EE200000391A (es) |
| GB (1) | GB9726987D0 (es) |
| GT (1) | GT199800203A (es) |
| HN (1) | HN1998000193A (es) |
| HR (1) | HRP20000419A2 (es) |
| HU (1) | HUP0100611A3 (es) |
| ID (1) | ID25449A (es) |
| IL (1) | IL136867A0 (es) |
| IS (1) | IS5542A (es) |
| JO (1) | JO2065B1 (es) |
| MA (1) | MA26587A1 (es) |
| NO (1) | NO20003211L (es) |
| NZ (1) | NZ505254A (es) |
| PA (1) | PA8465101A1 (es) |
| PE (1) | PE20000063A1 (es) |
| PL (1) | PL341392A1 (es) |
| SK (1) | SK9592000A3 (es) |
| SV (1) | SV1998000151A (es) |
| TR (1) | TR200001970T2 (es) |
| WO (1) | WO1999032462A1 (es) |
| YU (1) | YU39600A (es) |
| ZA (1) | ZA9811725B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0002666D0 (en) | 2000-02-04 | 2000-03-29 | Univ London | Blockade of voltage dependent sodium channels |
| PT1458386E (pt) * | 2001-12-27 | 2007-06-04 | Ortho Mcneil Pharm Inc | ''aroilpirrole-heteroarilo e metanóis úteis para o tratamento de um distúrbio do sistema nervoso central'' |
| EP1524981B1 (en) * | 2002-07-29 | 2009-03-11 | Glaxo Group Limited | Sustained release formulations comprising lamotrigine |
| JP2006515326A (ja) * | 2003-01-30 | 2006-05-25 | ダイノジェン ファーマシューティカルズ， インコーポレイテッド | 胃腸管障害を処置するためのナトリウムチャネルモジュレーターの使用 |
| MY142651A (en) | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
| DE10332472A1 (de) * | 2003-07-16 | 2005-02-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol für die Behandlung von Tinnitus |
| WO2005018627A1 (en) * | 2003-08-25 | 2005-03-03 | Newron Pharmaceuticals, Spa | Alpha-aminoamide derivatives useful as anti-inflammatory agents |
| US20060115865A1 (en) * | 2004-10-25 | 2006-06-01 | Anlong Ouyang | Lamotrigine analogs |
| GB201111712D0 (en) | 2011-07-08 | 2011-08-24 | Gosforth Ct Holdings Pty Ltd | Pharmaceutical compositions |
| TWI651310B (zh) | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
| SG11201800698VA (en) | 2015-08-17 | 2018-03-28 | Japan Tobacco Inc | Hydroxytriazine compound and medical use thereof |
| ES2770143T3 (es) * | 2018-02-13 | 2020-06-30 | Fis Fabbrica Italiana Sintetici Spa | Nuevo procedimiento eficiente para la preparación de sitagliptina |
| CN114796146B (zh) * | 2022-04-28 | 2023-03-28 | 上海奥科达医药科技股份有限公司 | 一种拉莫三嗪的缓释制剂及其制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3637688A (en) | 1970-01-09 | 1972-01-25 | American Home Prod | 6-(fluoro and trifluoromethyl phenyl)-3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines |
| EP0021120B1 (en) | 1979-06-01 | 1983-04-06 | The Wellcome Foundation Limited | 3,5-diamino-1,2,4-triazine derivatives, process for preparing such compounds and pharmaceutical compositions containing them |
| JPS5625169A (en) | 1979-06-01 | 1981-03-10 | Wellcome Found | Triazine derivative |
| EP0024351B1 (en) | 1979-08-16 | 1984-10-31 | The Wellcome Foundation Limited | Solid pharmaceutical formulation containing substitued phenyl-triazines |
| GB8328757D0 (en) | 1983-10-27 | 1983-11-30 | Wellcome Found | Chemical compounds |
| GB9012316D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
| GB9012312D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
| GB9012311D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
| GB9203483D0 (en) | 1992-02-19 | 1992-04-08 | Wellcome Found | Anti-inflammatory compounds |
| DK0644763T3 (da) | 1992-06-12 | 1997-07-28 | Wellcome Found | Anvendelse af 3,5-diamino-6-(2,3-dichlorphenyl)-1,2,4-triacin-isethionat til behandlingen og forebyggelsen af afhængighed, tolerance og sensitivering af medikamenter |
| WO1994014780A1 (en) | 1992-12-18 | 1994-07-07 | The Wellcome Foundation Limited | Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors |
| US5866597A (en) | 1993-03-19 | 1999-02-02 | Glaxo Wellcome Inc. | Use of triazine compounds for the treatment of memory and learning disorders |
| GB9305692D0 (en) | 1993-03-19 | 1993-05-05 | Wellcome Found | Therapeutic triazine compounds and use |
| GB9426448D0 (en) | 1994-12-30 | 1995-03-01 | Wellcome Found | Process |
| FR2741879A1 (fr) | 1995-12-05 | 1997-06-06 | Esteve Labor Dr | Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament |
-
1997
- 1997-12-22 GB GBGB9726987.2A patent/GB9726987D0/en not_active Ceased
-
1998
- 1998-12-18 AR ARP980106526A patent/AR014146A1/es not_active Application Discontinuation
- 1998-12-18 EA EA200000561A patent/EA200000561A1/ru unknown
- 1998-12-18 IL IL13686798A patent/IL136867A0/xx unknown
- 1998-12-18 US US09/582,058 patent/US6265405B1/en not_active Expired - Fee Related
- 1998-12-18 HR HR20000419A patent/HRP20000419A2/hr not_active Application Discontinuation
- 1998-12-18 TR TR2000/01970T patent/TR200001970T2/xx unknown
- 1998-12-18 JP JP2000525399A patent/JP2001526275A/ja active Pending
- 1998-12-18 SV SV1998000151A patent/SV1998000151A/es unknown
- 1998-12-18 EE EEP200000391A patent/EE200000391A/xx unknown
- 1998-12-18 HU HU0100611A patent/HUP0100611A3/hu unknown
- 1998-12-18 EP EP98966635A patent/EP1042304A1/en not_active Withdrawn
- 1998-12-18 CA CA002315620A patent/CA2315620A1/en not_active Abandoned
- 1998-12-18 PL PL98341392A patent/PL341392A1/xx unknown
- 1998-12-18 NZ NZ505254A patent/NZ505254A/en unknown
- 1998-12-18 AU AU24147/99A patent/AU753874B2/en not_active Ceased
- 1998-12-18 KR KR1020007006947A patent/KR20010024800A/ko not_active Withdrawn
- 1998-12-18 WO PCT/EP1998/008273 patent/WO1999032462A1/en not_active Ceased
- 1998-12-18 AP APAP/P/2000/001846A patent/AP2000001846A0/en unknown
- 1998-12-18 SK SK959-2000A patent/SK9592000A3/sk unknown
- 1998-12-18 CO CO98075403A patent/CO5011066A1/es unknown
- 1998-12-18 ID IDW20001416A patent/ID25449A/id unknown
- 1998-12-18 CN CN98813745A patent/CN1284951A/zh active Pending
- 1998-12-18 BR BR9814495-2A patent/BR9814495A/pt not_active IP Right Cessation
- 1998-12-18 YU YU39600A patent/YU39600A/sh unknown
- 1998-12-21 ZA ZA9811725A patent/ZA9811725B/xx unknown
- 1998-12-21 PE PE1998001255A patent/PE20000063A1/es not_active Application Discontinuation
- 1998-12-21 JO JO19982065A patent/JO2065B1/en active
- 1998-12-21 PA PA19988465101A patent/PA8465101A1/es unknown
- 1998-12-22 MA MA25403A patent/MA26587A1/fr unknown
- 1998-12-22 GT GT199800203A patent/GT199800203A/es unknown
-
1999
- 1999-12-21 HN HN1998000193A patent/HN1998000193A/es unknown
-
2000
- 2000-06-20 IS IS5542A patent/IS5542A/is unknown
- 2000-06-21 NO NO20003211A patent/NO20003211L/no unknown
-
2001
- 2001-07-06 US US09/899,198 patent/US6465461B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL116998A0 (en) | Novel indoline compounds processes for their preparation and their use for the treatment of CNS disorders | |
| EP0889888A4 (en) | NEW TREATMENT OF LESIONS IN THE CENTRAL NERVOUS SYSTEM | |
| EP0889887A4 (en) | TREATMENT OF CENTRAL NERVOUS SYSTEM INJURIES | |
| PL336290A1 (en) | Sulphonamides for treating endothelin-involving disorders | |
| IL138129A (en) | Composition for therapy of estrogen-associated disorders | |
| IL134289A0 (en) | Methods for treating neurological deficits | |
| IL141263A0 (en) | Methods for treatment of neurological disorders | |
| AP9801414A0 (en) | Combination effective for the treatment of impotence | |
| HUP0100611A3 (en) | Triazine compounds for treatment of cns disorders | |
| IL145696A0 (en) | Method for the treatment of neurological or neuropsychiatric disorders | |
| IL117016A0 (en) | Purification of melamine | |
| GR3036917T3 (en) | Process for the preparation of pyrimidine compounds | |
| PL332821A1 (en) | Pyrazolydinones for treating potency disorders | |
| GB2318350B (en) | Process for purification of hydrochlorofluoroethanes | |
| HUP0004030A3 (en) | Process for the purification of aspartame derivative | |
| SI1468686T1 (sl) | S-metil-dihidro-ziprazidon za zdravljenje psihiatricnih motenj | |
| HK1028609A (en) | Triazine compounds for treatment of cns disorders | |
| HU9902737D0 (en) | The use of aryl-cyclohexylamine derivatives against cns disorders | |
| IL139018A0 (en) | Paroxetine 10-camphorsulfonate for treatment of cns disorders | |
| IL122077A0 (en) | Epi-inositol compositions for the treatment of CNS disorders | |
| AU7521598A (en) | Aralkoxy-morphinan derivatives for treatment of cns disorders | |
| IL136949A0 (en) | 1,4-diazacycloheptane derivatives for the treatment of neurological disorders | |
| IL131765A0 (en) | Process for the purification of substituted p-nitrodiphenylethers | |
| SI1049672T1 (en) | Azetidinecarboxamide derivatives for treating cns disorders | |
| SI1049670T1 (en) | Azetidinecarboxamide derivatives for treating cns disorders |